Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration

Abstract

Rucaparib has antitumor activity in patients with mCRPC and a deleterious <i>BRCA</i> alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.